Pharmacogenetics of lithium response in bipolar disorder

Pharmacogenomics

Volumn 11, Issue 10, 2010, Pages 1439-1465

  McCarthy, Michael J ^a   Leckband, Susan G ^b   Kelsoe, John R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

bipolar disorder; circadian clock; CRE B; gene expression; genetic association; glutamate; GSK 3 ; lithium; pathways; pharmacogenetics

Indexed keywords

CELL CYCLE PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC NUCLEOTIDE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL; LITHIUM; MONOAMINE; NEUROTROPIN; PROTEIN KINASE C; X BOX BINDING PROTEIN 1;

ATROPHY; BIOINFORMATICS; BIPOLAR DISORDER; CELL MOTILITY; CORTICAL ATROPHY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; FAMILY HISTORY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MULTIGENE FAMILY; MYELINATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; PROTEIN METABOLISM; RELIABILITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; BIPOLAR DISORDER; GENETIC ASSOCIATION STUDIES; HUMANS; LITHIUM; PHARMACOGENETICS; PHENOTYPE; TREATMENT OUTCOME;

EID: 78149321346     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.127     Document Type: Review

References (203)

1. Judd LL, Akiskal HS, Schettler PJ et al.: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59(6), 530-537 (2002).
2. Martinez JM, Marangell LB, Simon NM et al.: Baseline predictors of serious adverse events at one year among patients with bipolar disorder in STEP-BD. Psychiatr. Serv. 56(12), 1541-1548 (2005).
3. Tondo L, Hennen J, Baldessarini RJ: Lower suicide risk with long-term lithium treatment in major affective illness: a meta-ana lysis. Acta. Psychiatr. Scand. 104(3), 163-172 (2001).
4. Perlis RH, Ostacher MJ, Patel JK et al.: Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry 163(2), 217-224 (2006).
5. Hirschfeld RM, Lewis L, Vornik LA: Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry 64(2), 161-174 (2003).
6. McGuffn P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A: The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch. Gen. Psychiatry 60(5), 497-502 (2003).
7. Licht RW, Vestergaard P, Rasmussen NA, Jepsen K, Brodersen A, Hansen PE: A lithium clinic for bipolar patients: 2-year outcome of the frst 148 patients. Acta. Psychiatr. Scand. 104(5), 387-390 (2001).
8. Vestergaard P, Schou M: Prospective studies on a lithium cohort. 1. General features. Acta. Psychiatr. Scand. 78(4), 421-426 (1988).
9. Berghofer A, Alda M, Adli M et al.: Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. J. Clin. Psychiatry. 69(12), 1860-1868 (2008).
10. Grof P: Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J. Clin. Psychiatry. 64(Suppl. 5), 53-61 (2003).
11. Zvolsky P, Dostal T, Vinarova E, Soucek K: Genealogic study of patients suffering from primary affective disorder and treated with lithium. Act. Nerv. Super (Praha). 15(2), 90 (1973).
12. Mendlewicz J, Fieve RR, Stallone F: Relationship between the effectiveness of lithium therapy and family history. Am. J. Psychiatry 130(9), 1011-1013 (1973).
13. Grof P, Alda M, Grof E, Zvolsky P, Walsh M: Lithium response and genetics of affective disorders. J. Affect. Disord. 32(2), 85-95 (1994).
14. Smeraldi E, Petroccione A, Gasperini M, Macciardi F, Orsini A, Kidd KK: Outcomes on lithium treatment as a tool for genetic studies in affective disorders. J. Affect. Disord. 6(2), 139-151 (1984).
15. Mendlewicz J, Verbanck P, Linkowski P, Wilmotte J: Lithium accumulation in erythrocytes of manic-depressive patients: an in vivo twin study. Br. J. Psychiatry 133, 436-444 (1978).
16. Grof P, Duffy A, Alda M, Hajek T: Lithium response across generations. Acta. Psychiatr. Scand. 120(5), 378-385 (2009).
17. Turecki G, Grof P, Grof E et al.: Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol. Psychiatry 6(5), 570-578 (2001).
18. Turecki G, Grof P, Cavazzoni P et al.: Evidence for a role of phospholipase C-g1 in the pathogenesis of bipolar disorder. Mol. Psychiatry 3(6), 534-538 (1998). (Pubitemid 28515530)
19. Lovlie R, Berle JO, Stordal E, Steen VM: The phospholipase C-g1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatr. Genet. 11(1), 41-43 (2001).
20. Cade JF: Lithium salts in the treatment of psychotic excitement. Med. J. Aust. 2(10), 349-352 (1949).
21. Agam G, Bersudsky Y, Berry GT, Moechars D, Lavi-Avnon Y, Belmaker RH: Knockout mice in understanding the mechanism of action of lithium. Biochem. Soc. Trans. 37(Pt 5), 1121-1125 (2009).
22. Chen G, Manji HK: The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr. Opin Psychiatry 19(3), 313-323 (2006).
23. Zarate CA Jr, Singh J, Manji HK: Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry 59(11), 1006-1020 (2006).
24. Quiroz JA, Gould TD, Manji HK: Molecular effects of lithium. Mol. Interv. 4(5), 259-272 (2004).
25. 2+ the underlying theme in the proposed mechanisms for the pharmacological action of lithium salts in bipolar disorder? Acc. Chem. Res. 39(4), 283-291 (2006).
26. Ryves WJ, Harwood AJ: Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. 280(3), 720-725 (2001).
27. Ebstein R, Belmaker R, Grunhaus L, Rimon R: Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans. Nature 259(5542), 411-413 (1976).
28. Belmaker RH: Receptors, adenylate cyclase, depression, and lithium. Biol. Psychiatry 16(4), 333-350 (1981).
29. Mann L, Heldman E, Shaltiel G, Belmaker RH, Agam G: Lithium preferentially inhibits adenylyl cyclase V and VII isoforms. Int. J. Neuropsychopharmacol. 11(4), 533-539 (2008).
30. Avissar S, Schreiber G, Danon A, Belmaker RH: Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 331(6155), 440-442 (1988).
31. Colin SF, Chang HC, Mollner S et al.: Chronic lithium regulates the expression of adenylate cyclase and Gi-protein a subunit in rat cerebral cortex. Proc. Natl Acad. Sci. USA 88(23), 10634-10637 (1991).
32. Avissar S, Schreiber G: Ziskind-Somerfeld research Award. The involvement of guanine nucleotide binding proteins in the pathogenesis and treatment of affective disorders. Biol. Psychiatry 31(5), 435-459 (1992).
33. Mork A, Geisler A: Effects of chronic lithium treatment on agonist-enhanced extracellular concentrations of cyclic AMP in the dorsal hippocampus of freely moving rats. J. Neurochem. 65(1), 134-139 (1995).
34. Sherman WR, Gish BG, Honchar MP, Munsell LY: Effects of lithium on phosphoinositide metabolism in vivo. Fed. Proc. 45(11), 2639-2646 (1986).
35. Berridge MJ, Downes CP, Hanley MR: Neural and developmental actions of lithium: a unifying hypothesis. Cell 59(3), 411-419 (1989).
36. Wang HY, Friedman E: Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology (Berl.) 99(2), 213-218 (1989).
37. Manji HK, Etcheberrigaray R, Chen G, Olds JL: Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the a isozyme. J. Neurochem. 61(6), 2303-2310 (1993).
38. Friedman E, Hoau Yan W, Levinson D, Connell TA, Singh H: Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol. Psychiatry 33(7), 520-525 (1993).
39. Jope RS, Williams MB: Lithium and brain signal transduction systems. Biochem. Pharmacol. 47(3), 429-441 (1994).
40. Jenkinson S, Patel N, Nahorski SR, Challiss RA: Comparative effects of lithium on the phosphoinositide cycle in rat cerebral cortex, hippocampus, and striatum. J. Neurochem. 61(3), 1082-1090 (1993).
41. Gray DW, Challiss RA, Nahorski SR: Differential effects of lithium on muscarinic cholinoceptor-stimulated CMP-phosphatidate accumulation in cerebellar granule cells, CHO-M3 cells, and SH-SY5Y neuroblastoma cells. J. Neurochem. 63(4), 1354-1360 (1994).
42. Klein PS, Melton DA: A molecular mechanism for the effect of lithium on development. Proc. Natl Acad. Sci. USA 93(16), 8455-8459 (1996).
43. Gould TD, Manji HK: The Wnt signaling pathway in bipolar disorder. Neuroscientist 8(5), 497-511 (2002).
44. Arikkath J, Reichardt LF: Cadherins and catenins at synapses: roles in synaptogenesis and synaptic plasticity. Trends Neurosci. 31(9), 487-494 (2008).
45. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378(6559), 785-789 (1995).
46. Eldar-Finkelman H, Seger R, Vandenheede JR, Krebs EG: Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. J. Biol. Chem. 270(3), 987-990 (1995).
47. Chen G, Huang LD, Jiang YM, Manji HK: The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72(3), 1327-1330 (1999).
48. Gould TD, Einat H, Bhat R, Manji HK: AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 7(4), 387-390 (2004).
49. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H: Rapid antidepressive-like activity of specifc glycogen synthase kinase-3 inhibitor and its effect on p-catenin in mouse hippocampus. Biol. Psychiatry 55(8), 781-784 (2004).
50. Kozikowski AP, Gaisina IN, Yuan H et al.: Structure-based design leads to the identifcation of lithium mimetics that block mania-like effects in rodents. possible new GSK-3p therapies for bipolar disorders. J. Am. Chem. Soc. 129(26), 8328-8332 (2007).
51. O'Brien WT, Harper AD, Jove F et al.: Glycogen synthase kinase-3p haploinsuffciency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24(30), 6791-6798 (2004).
52. Prickaerts J, Moechars D, Cryns K et al.: Transgenic mice overexpressing glycogen synthase kinase 3p: a putative model of hyperactivity and mania. J. Neurosci. 26(35), 9022-9029 (2006).
53. Malinow R, Malenka RC: AMPA receptor traffcking and synaptic plasticity. Annu. Rev. Neurosci. 25, 103-126 (2002).
54. Malenka RC: Synaptic plasticity and AMPA receptor traffcking. Ann. NY Acad. Sci. 1003, 1-11 (2003).
55. Szabo ST, Machado-Vieira R, Yuan P et al.: Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology 56(1), 47-55 (2009).
56. Du J, Gray NA, Falke CA et al.: Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J. Neurosci. 24(29), 6578-6589 (2004).
57. Du J, Creson TK, Wu LJ et al.: The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J. Neurosci. 28(1), 68-79 (2008).
58. Du J, Suzuki K, Wei Y et al.: The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32(4), 793-802 (2007).
59. Kim HJ, Thayer SA: Lithium increases synapse formation between hippocampal neurons by depleting phosphoinositides. Mol. Pharmacol. 75(5), 1021-1030 (2009).
60. Drevets WC, Price JL, Simpson JR Jr et al.: Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386(6627), 824-827 (1997).
61. Takahashi T, Malhi GS, Wood SJ et al.: Gray matter reduction of the superior temporal gyrus in patients with established bipolar I disorder. J. Affect. Disord. 123(1-3), 276-282 (2009).
62. Fornito A, Yucel M, Pantelis C: Reconciling neuroimaging and neuropathological fndings in schizophrenia and bipolar disorder. Curr. Opin Psychiatry 22(3), 312-319 (2009).
63. Yucel K, McKinnon MC, Taylor VH et al.: Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology (Berl.) 195(3), 357-367 (2007).
64. Moore GJ, Cortese BM, Glitz DA et al.: A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J. Clin. Psychiatry. 70(5), 699-705 (2009).
65. Nonaka S, Hough CJ, Chuang DM: Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium infux. Proc. Natl Acad. Sci. USA 95(5), 2642-2647 (1998).
66. Williams RS, Cheng L, Mudge AW, Harwood AJ: A common mechanism of action for three mood-stabilizing drugs. Nature 417(6886), 292-295 (2002).
67. Owen R, Gordon-Weeks PR: Inhibition of glycogen synthase kinase 3p in sensory neurons in culture alters flopodia dynamics and microtubule distribution in growth cones. Mol. Cell Neurosci. 23(4), 626-637 (2003).
68. Wexler EM, Geschwind DH, Palmer TD: Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol. Psychiatry. 13(3), 285-292 (2008).
69. Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3p regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12(22), 3499-3511 (1998).
70. Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S: Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J. Biol. Chem. 277(12), 9684-9689 (2002).
71. Kulikov R, Boehme KA, Blattner C: Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol. Cell Biol. 25(16), 7170-7180 (2005).
72. Zhao C, Deng W, Gage FH: Mechanisms and functional implications of adult neurogenesis. Cell 132(4), 645-660 (2008).
73. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK: Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75(4), 1729-1734 (2000).
74. Kim JS, Chang MY, Yu IT et al.: Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo. J. Neurochem. 89(2), 324-336 (2004).
75. Tseng M, Alda M, Xu L et al.: BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder. J. Psychiatry Neurosci. 33(5), 449-453 (2008).
76. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S: Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl.) 158(1), 100-106 (2001).
77. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM: Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43 (7), 1173-1179 (2002).
78. Chen G, Zeng WZ, Yuan PX et al.: The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72(2), 879-882 (1999).
79. Manji HK, Moore GJ, Chen G: Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J. Clin. Psychiatry. 61(Suppl. 9), 82-96 (2000).
80. McClung CA: Circadian genes, rhythms and the biology of mood disorders. Pharmacol. Ther. 114(2), 222-232 (2007).
81. Abe M, Herzog ED, Block GD: Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons. Neuroreport 11(14), 3261-3264 (2000).
82. Kripke DF, Judd LL, Hubbard B, Janowsky DS, Huey LY: The effect of lithium carbonate on the circadian rhythm of sleep in normal human subjects. Biol. Psychiatry 14(3), 545-548 (1979).
83. Kripke DF, Wyborney VG: Lithium slows rat circadian activity rhythms. Life Sci. 26(16), 1319-1321 (1980).
84. Welsh DK, Moore-Ede MC: Lithium lengthens circadian period in a diurnal primate, Saimiri sciureus. Biol. Psychiatry 28(2), 117-126 (1990).
85. Takahashi JS, Hong HK, Ko CH, McDearmon EL: The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat. Rev. Genet. 9(10), 764-775 (2008).
86. Roybal K, Theobold D, Graham A et al.: Mania-like behavior induced by disruption of CLOCK. Proc. Natl Acad. Sci. USA 104(15), 6406-6411 (2007).
87. Kishi T, Kitajima T, Ikeda M et al.: Association ana lysis of nuclear receptor Rev-erb a gene (NR1D1) with mood disorders in the Japanese population. Neurosci. Res. 62(4), 211-215 (2008).
88. Severino G, Manchia M, Contu P et al.: Association study in a Sardinian sample between bipolar disorder and the nuclear receptor REV-ERBa gene, a critical component of the circadian clock system. Bipolar Disord. 11(2), 215-220 (2009).
89. Kripke DF, Nievergelt CM, Joo E, Shekhtman T, Kelsoe JR: Circadian polymorphisms associated with affective disorders. J. Circadian Rhythms. 7, 2 (2009).
90. Yin L, Wang J, Klein PS, Lazar MA: Nuclear receptor Rev-erba is a critical lithium-sensitive component of the circadian clock. Science 311(5763), 1002-1005 (2006).
91. Gimble JM, Floyd ZE, Bunnell BA: The 4th dimension and adult stem cells: can timing be everything? J. Cell Biochem. 107(4), 569-578 (2009).
92. Borgs L, Beukelaers P, Vandenbosch R et al.: Period 2 regulates neural stem/progenitor cell proliferation in the adult hippocampus. BMC Neurosci. 10, 30 (2009).
93. Bosetti F, Seemann R, Bell JM et al.: Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. Brain Res. Bull. 57(2), 205-209 (2002).
94. Sun X, Young LT, Wang JF et al.: Identifcation of lithium-regulated genes in cultured lymphoblasts of lithium-responsive subjects with bipolar disorder. Neuropsychopharmacology 29(4), 799-804 (2004).
95. Brandish PE, Su M, Holder DJ et al.: Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex. Neuron 45(6), 861-872 (2005).
96. Zhang WV, Jullig M, Connolly AR, Stott NS: Early gene response in lithium chloride induced apoptosis. Apoptosis 10(1), 75-90 (2005).
97. McQuillin A, Rizig M, Gurling HM: A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet. Genomics 17(8), 605-617 (2007).
98. Chetcuti A, Adams LJ, Mitchell PB, Schofeld PR: Microarray gene expression profling of mouse brain mRNA in a model of lithium treatment. Psychiatr. Genet. 18(2), 64-72 (2008).
99. Seelan RS, Khalyfa A, Lakshmanan J, Casanova MF, Parthasarathy RN: Deciphering the lithium transcriptome: microarray profling of lithium-modulated gene expression in human neuronal cells. Neuroscience 151(4), 1184-1197 (2008).
100. Fatemi SH, Reutiman TJ, Folsom TD: The role of lithium in modulation of brain genes: relevance for aetiology and treatment of bipolar disorder. Biochem. Soc. Trans. 37(Pt 5), 1090-1095 (2009).
101. Plant KE, Anderson E, Simecek N et al.: The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol. Appl. Pharmacol. 235(1), 124-134 (2009).
102. Mendes CT, Mury FB, de Sa Moreira E et al.: Lithium reduces Gsk3b mRNA levels: implications for Alzheimer disease. Eur. Arch. Psychiatry Clin. Neurosci. 259(1), 16-22 (2009).
103. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T: Molecular characterization of bipolar disorder by comparing gene expression profles of postmortem brains of major mental disorders. Mol. Psychiatry 9(4), 406-416 (2004).
104. Kelsoe JR, Spence MA, Loetscher E et al.: A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22. Proc. Natl Acad. Sci. USA 98(2), 585-590 (2001).
105. Liang SG, Sadovnick AD, Remick RA, Keck PE, McElroy SL, Kelsoe JR: A linkage disequilibrium study of bipolar disorder and microsatellite markers on 22q13. Psychiatr. Genet. 12(4), 231-235 (2002).
106. Chowdari K V, Mirnics K, Semwal P et al.: Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum. Mol. Genet. 11(12), 1373-1380 (2002).
107. Cordeiro Q, Talkowski ME, Chowdari K V, Wood J, Nimgaonkar V, Vallada H: Association and linkage ana lysis of RGS4 polymorphisms with schizophrenia and bipolar disorder in Brazil. Genes Brain Behav. 4(1), 45-50 (2005).
108. Chang Q, Pang JC, Li KK, Poon WS, Zhou L, Ng HK: Promoter hypermethylation profle of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors. Hum. Pathol. 36(12), 1265-1272 (2005).
109. Whang YM, Kim YH, Kim JS, Yoo YD: RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression. Cancer Res. 65(9), 3682-3690 (2005).
110. Lloyd AJ, Moore PB, Cousins DA et al.: White matter lesions in euthymic patients with bipolar disorder. Acta. Psychiatr. Scand. 120(6), 481-491 (2009).
111. Navone F, Consalez GG, Sardella M et al.: Expression of KIF3C kinesin during neural development and in vitro neuronal differentiation. J. Neurochem. 77(3), 741-753 (2001).
112. Sbai O, Ferhat L, Bernard A et al.: Vesicular traffcking and secretion of matrix metalloproteinases-2,-9 and tissue inhibitor of metalloproteinases-1 in neuronal cells. Mol. Cell Neurosci. 39(4), 549-568 (2008).
113. Michaluk P, Mikasova L, Groc L, Frischknecht R, Choquet D, Kaczmarek L: Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin b 1 signaling. J. Neurosci. 29(18), 6007-6012 (2009).
114. Ferreira MA, O'Donovan MC, Meng YA et al.: Collaborative genome-wide association ana lysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 40(9), 1056-1058 (2008).
115. Sklar P, Smoller JW, Fan J et al.: Whole-genome association study of bipolar disorder. Mol. Psychiatry. 13(6), 558-569 (2008).
116. Perlis RH, Purcell S, Fagerness J et al.: Family-based association study of lithium-related and other candidate genes in bipolar disorder. Arch. Gen. Psychiatry 65(1), 53-61 (2008).
117. Atz ME, Rollins B, Vawter MP: NCAM1 association study of bipolar disorder and schizophrenia: polymorphisms and alternatively spliced isoforms lead to similarities and differences. Psychiatr. Genet. 17(2), 55-67 (2007).
118. Zhou R, Yuan P, Wang Y et al.: Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34(6), 1395-1405 (2009).
119. Chen H, Wang N, Burmeister M, McInnis MG: MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int. J. Neuropsychopharmacol. (2009) (Epub ahead of print).
120. Purcell SM, Wray NR, Stone JL et al.: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460(7256), 748-752 (2009).
121. Manolio TA, Collins FS, Cox NJ et al.: Finding the missing heritability of complex diseases. Nature 461(7265), 747-753 (2009).
122. Zhang D, Cheng L, Qian Y et al.: Singleton deletions throughout the genome increase risk of bipolar disorder. Mol. Psychiatry 14(4), 376-380 (2009).
123. Knight HM, Pickard BS, Maclean A et al.: A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression. Am. J. Hum. Genet. 85(6), 833-846 (2009).
124. McCarthy SE, Makarov V, Kirov G et al.: Microduplications of 16p11.2 are associated with schizophrenia. Nat. Genet. 41(11), 1223-1227 (2009).
125. Mill J, Tang T, Kaminsky Z et al.: Epigenomic profling reveals DNA-methylation changes associated with major psychosis. Am. J. Hum. Genet. 82(3), 696-711 (2008).
126. Smith EN, Bloss CS, Badner JA et al.: Genome-wide association study of bipolar disorder in European American and African American individuals. Mol. Psychiatry. 14(8), 755-763 (2009).
127. Baum AE, Hamshere M, Green E et al.: Meta-ana lysis of two genome-wide association studies of bipolar disorder reveals important points of agreement. Mol. Psychiatry. 13(5), 466-467 (2008).
128. Garnham J, Munro A, Slaney C et al.: Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J. Affect. Disord. 104(1-3), 185-190 (2007).
129. Grof P, Duffy A, Cavazzoni P et al.: Is response to prophylactic lithium a familial trait? J. Clin. Psychiatry. 63(10), 942-947 (2002).
130. Serretti A, Lilli R, Smeraldi E: Pharmacogenetics in affective disorders. Eur. J. Pharmacol. 438(3), 117-128 (2002).
131. Serretti A, Lilli R, Lorenzi C, Gasperini M, Smeraldi E: Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J. Psychiatr. Res. 33(5), 371-377 (1999).
132. Rybakowski JK, Dmitrzak-Weglarz M, Suwalska A, Leszczynska-Rodziewicz A, Hauser J: Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder. Pharmacopsychiatry 42(1), 20-22 (2009).
133. Severino G, Congiu D, Serreli C et al.: A48G polymorphism in the D1 receptor genes associated with bipolar I disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134B(1), 37-38 (2005).
134. Manchia M, Congiu D, Squassina A et al.: No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. Psychiatry Res. 169(2), 164-166 (2009).
135. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A et al.: Association studies of 5-HT2A and 5-HT2C serotonin receptor gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacol. Rep. 57(6), 761-765 (2005).
136. Serretti A, Lilli R, Lorenzi C, Franchini L, Smeraldi E: Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. Int. J. Neuropsychopharmacol. 1(2), 125-129 (1998).
137. Serretti A, Lilli R, Lorenzi C et al.: Dopamine receptor D2 and D4 genes, GABA(A) a-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res. 87(1), 7-19 (1999).
138. Serretti A, Lorenzi C, Lilli R, Smeraldi E: Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J. Psychiatr. Res. 34(2), 89-98 (2000). (Pubitemid 30176115)
139. Serretti A, Lorenzi C, Lilli R, Mandelli L, Pirovano A, Smeraldi E: Pharmacogenetics of lithium prophylaxis in mood disorders: ana lysis of COMT, MAO-A, and Gb3 variants. Am. J. Med. Genet. 114(4), 370-379 (2002).
140. Turecki G, Grof P, Cavazzoni P et al.: MAOA: association and linkage studies with lithium responsive bipolar disorder. Psychiatr. Genet. 9(1), 13-16 (1999).
141. Collier DA, Stober G, Li T et al.: A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol. Psychiatry 1(6), 453-460 (1996).
142. Mendlewicz J, Massat I, Souery D et al.: Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. Eur. J. Hum. Genet. 12(5), 377-382 (2004).
143. Mansour HA, Talkowski ME, Wood J et al.: Serotonin gene polymorphisms and bipolar I disorder: focus on the serotonin transporter. Ann. Med. 37(8), 590-602 (2005).
144. Mundo E, Walker M, Tims H, Macciardi F, Kennedy JL: Lack of linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and bipolar disorder. Am. J. Med. Genet. 96(3), 379-383 (2000).
145. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL: The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary fndings. Arch. Gen. Psychiatry 58(6), 539-544 (2001).
146. Ferreira Ade A, Neves FS, da Rocha FF et al.: The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder. J. Affect. Disord. 112(1-3), 267-272 (2009).
147. Neves FS, Silveira G, Romano-Silva MA et al.: Is the 5-HTTLPR polymorphism associated with bipolar disorder or with suicidal behavior of bipolar disorder patients? Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(1), 114-116 (2008).
148. Caspi A, Sugden K, Mofftt TE et al.: Infuence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631), 386-389 (2003).
149. Masoliver E, Menoyo A, Perez V et al.: Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatr. Genet. 16(1), 25-29 (2006).
150. Serretti A, Malitas PN, Mandelli L et al.: Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics J. 4(4), 267-273 (2004).
151. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E: Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J. 1(1), 71-77 (2001).
152. Rybakowski JK, Suwalska A, Czerski PM, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J: Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol. Rep. 57(1), 124-127 (2005).
153. Rybakowski JK, Suwalska A, Skibinska M, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J: Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(6), 820-823 (2007).
154. Stamm TJ, Adli M, Kirchheiner J et al.: Serotonin transporter gene and response to lithium augmentation in depression. Psychiatr. Genet. 18(2), 92-97 (2008).
155. Lazary J, Lazary A, Gonda X et al.: New evidence for the association of the serotonin transporter gene (SLC6A4) haplotypes, threatening life events, and depressive phenotype. Biol. Psychiatry 64(6), 498-504 (2008).
156. Risch N, Herrell R, Lehner T et al.: Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-ana-lysis. JAMA 301(23), 2462-2471 (2009).
157. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK: The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 8(3), 259-268 (1998).
158. Michelon L, Meira-Lima I, Cordeiro Q et al.: Association study of the INPP1, 5HTT, BDNF, AP-2b and GSK-3b gene variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci. Lett. 403(3), 288-293 (2006).
159. Dimitrova A, Milanova V, Krastev S et al.: Association study of myo-inositol monophosphatase 2 (IMPA2) polymorphisms with bipolar affective disorder and response to lithium treatment. Pharmacogenomics J. 5(1), 35-41 (2005).
160. Manchia M, Squassina A, Congiu D et al.: Interacting genes in lithium prophylaxis: preliminary results of an exploratory ana lysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients. Neurosci. Lett. 467(2), 67-71 (2009).
161. Lau KF, Miller CC, Anderton BH, Shaw PC: Molecular cloning and characterization of the human glycogen synthase kinase-3b promoter. Genomics 60(2), 121-128 (1999).
162. Kwok JB, Hallupp M, Loy CT et al.: GSK3b polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 58(6), 829-839 (2005).
163. Benedetti F, Serretti A, Pontiggia A et al.: Long-term response to lithium salts in bipolar illness is infuenced by the glycogen synthase kinase 3-b-50 T/C SNP. Neurosci. Lett. 376(1), 51-55 (2005).
164. Adli M, Hollinde DL, Stamm T et al.: Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-b-50T/C single nucleotide polymorphism. Biol. Psychiatry 62(11), 1295-1302 (2007).
165. Bremer T, Diamond C, McKinney R et al.: The pharmacogenetics of lithium response depends upon clinical co-morbidity. Mol. Diagn. Ther. 11(3), 161-170 (2007).
166. Szczepankiewicz A, Rybakowski JK, Suwalska A et al.: Association study of the glycogen synthase kinase-3b gene polymorphism with prophylactic lithium response in bipolar patients. World. J. Biol. Psychiatry 7(3), 158-161 (2006).
167. Campos-de-Sousa S, Guindalini C, Tondo L et al.: Nuclear receptor Rev-Erb-{a} circadian gene variants and lithium carbonate prophylaxis in bipolar affective disorder. J. Biol. Rhythms 25(2), 132-137 (2010).
168. Benedetti F, Dallaspezia S, Fulgosi MC et al.: Actimetric evidence that CLOCK 3111 T/C SNP infuences sleep and activity patterns in patients affected by bipolar depression. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(5), 631-635 (2007).
169. Szczepankiewicz A, Skibinska M, Suwalska A, Hauser J, Rybakowski JK: No association of three GRIN2B polymorphisms with lithium response in bipolar patients. Pharmacol. Rep. 61(3), 448-452 (2009).
170. Silberberg G, Levit A, Collier D et al.: Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenet. Genomics 18(5), 403-412 (2008).
171. Hashimoto R, Okada T, Kato T et al.: The breakpoint cluster region gene on chromosome 22q11 is associated with bipolar disorder. Biol. Psychiatry 57(10), 1097-1102 (2005).
172. Masui T, Hashimoto R, Kusumi I et al.: A possible association between missense polymorphism of the breakpoint cluster region gene and lithium
173. Szczepankiewicz A, Rybakowski JK, Skibinska M et al.: FYN kinase gene: another glutamatergic gene associated with bipolar disorder? Neuropsychobiology. 59(3), 178-183 (2009).
174. Szczepankiewicz A, Skibinska M, Suwalska A, Hauser J, Rybakowski JK: The association study of three FYN polymorphisms with prophylactic lithium response in bipolar patients. Hum. Psychopharmacol. 24(4), 287-291 (2009).
175. Mamdani F, Alda M, Grof P, Young LT, Rouleau G, Turecki G: Lithium response and genetic variation in the CREB family of genes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(4), 500-504 (2008).
176. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A et al.: Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 9(11), 1595-1603 (2008).
177. Masui T, Hashimoto R, Kusumi I et al.: Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatr. Genet. 16(2), 49-50 (2006).
178. Aitchison K, Serretti A, Goldman D, Curran S, Drago A, Malhotra AK: The 8th annual pharmacogenetics in psychiatry meeting report. Pharmacogenomics J. 9(6), 358-361 (2009).
179. Leckband SG, DeModena A, McKinney R, Shekhtman T, Kelsoe JR: Lithium response is associated with the NTRK2 gene in a prospective study. Presented at: 17th Annual Molecular Psychiatry Meeting. UT, USA (2010)
180. Kakiuchi C, Iwamoto K, Ishiwata M et al.: Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat. Genet. 35(2), 171-175 (2003).
181. Matigian N, Windus L, Smith H et al.: Expression profling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway. Mol. Psychiatry. 12(9), 815-825 (2007).
182. Cichon S, Buervenich S, Kirov G et al.: Lack of support for a genetic association of the XBP1 promoter polymorphism with bipolar disorder in probands of European origin. Nat. Genet. 36(8), 783-784 (2004).
183. Masui T, Hashimoto R, Kusumi I et al.: A possible association between the-116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int. J. Neuropsychopharmacol. 9(1), 83-88 (2006).
184. Kim B, Kim CY, Lee MJ, Joo YH: Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry Res. 168(3), 209-212 (2009).
185. Kato T, Kunugi H, Nanko S, Kato N: Mitochondrial DNA polymorphisms in bipolar disorder. J. Affect. Disord. 62(3), 151-164 (2001). (Pubitemid 32167082)
186. Washizuka S, Ikeda A, Kato N, Kato T: Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. Int. J. Neuropsychopharmacol. 6(4), 421-424 (2003).
187. Kato T, Iwayama Y, Kakiuchi C et al.: Gene expression and association analyses of LIM (PDLIM5) in bipolar disorder and schizophrenia. Mol. Psychiatry. 10(11), 1045-1055 (2005). (Pubitemid 41541990)
188. Squassina A, Congiu D, Manconi F et al.: The PDLIM5 gene and lithium prophylaxis: an association and gene expression ana lysis in Sardinian patients with bipolar disorder. Pharmacol. Res. 57(5), 369-373 (2008).
189. Mamdani F, Sequeira A, Alda M, Grof P, Rouleau G, Turecki G: No association between the PREP gene and lithium responsive bipolar disorder. BMC Psychiatry 7, 9 (2007).
190. Duffy A, Turecki G, Grof P et al.: Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder. J. Psychiatry Neurosci. 25(4), 353-358 (2000).
191. Perlis RH, Smoller JW, Ferreira MA et al.: A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am. J. Psychiatry. 166(6), 718-725 (2009).
192. Dedman A, Bass N, McQuillin A et al.: Whole-genome association study of response to lithium treatment in bipolar disorder. Presented at: World Congress of Psychiatric Genetics XVII. CA, USA (2009).
193. Wilke RA, Mareedu RK, Moore JH: The pathway less traveled: moving from candidate genes to candidate pathways in the analysis of genome-wide data from large scale pharmacogenetic association studies. Curr. Pharmacogenomics Pers. Med. 6(3), 150-159 (2008).
194. Kooloos WM, Wessels JA, van der Straaten T, Huizinga TW, Guchelaar HJ: Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. Drug Discov. Today 14(17-18), 837-844 (2009).
195. Hansen NT, Brunak S, Altman RB: Generating genome-scale candidate gene lists for pharmacogenomics. Clin. Pharmacol. Ther. 86(2), 183-189 (2009).
196. Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fbroblasts by defned factors. Cell 131(5), 861-872 (2007).
197. Dimos JT, Rodolfa KT, Niakan KK et al.: Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321(5893), 1218-1221 (2008).
198. Ebert AD, Yu J, Rose FF Jr et al.: Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457(7227), 277-280 (2009).
199. Holmans P, Green EK, Pahwa JS et al.: Gene ontology ana lysis of GWA study data sets provides insights into the biology of bipolar disorder. Am. J. Hum. Genet. 85(1), 13-24 (2009).
200. Perez-Torres S, Cortes R, Tolnay M, Probst A, Palacios JM, Mengod G: Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp. Neurol. 182(2), 322-334 (2003).
201. Uhl GR, Drgon T, Liu QR et al.: Genome-wide association for methamphetamine dependence: convergent results from 2 samples. Arch. Gen. Psychiatry 65(3), 345-355 (2008).
202. Barrett TB, Hauger RL, Kennedy JL et al.: Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder. Mol. Psychiatry 8(5), 546-557 (2003).
203. Barrett TB, Emberton JE, Nievergelt CM et al.: Further evidence for association of GRK3 to bipolar disorder suggests a second disease mutation. Psychiatr. Genet. 17(6), 315-322 (2007).